article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. Attendees will understand best practices for novel drug delivery design and development. The key active ingredient, cyclosporine, functions as a selective immunomodulatory drug.

article thumbnail

Nanoform sets a new near-term business target for 2021

The Pharma Data

Nanoform’s capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. Forward-Looking Statements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. What are cell-penetrating peptides?

article thumbnail

Nanoform launches technology for biologics and sets new near-term business target for 2021

The Pharma Data

Nanoform’s capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. Forward-Looking Statements.

article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. About XPhyto Therapeutics Corp. XPhyto Therapeutics Corp.

Drugs 52
article thumbnail

Mitigating the risks of cross-contamination during Oral Solid Dose (OSD) manufacturing

Pharmaceutical Technology

In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.